-Primary and key secondary endpoints met in both TRuE-V1 and TRuE-V2 studies
-Data will support planned U.S. and EU regulatory submissions for ruxolitinib cream in vitiligo in the second half of 2021
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients (age ≥12 years) with vitiligo.
Both the TRuE-V1 and TRuE-V2 studies met the primary endpoint (p